Assessment of China’s Hepatitis B treatment market

After COVID, the life sciences industry has seen a rapid acceleration of technological advancements, making it more critical than ever for industry players to keep abreast of current and emerging treatments for their respective therapeutic areas.

A major biopharmaceutical company sought a holistic assessment of the treatment market for Hepatitis B in China to aid strategic planning for existing and new products. A thorough analysis of this market was needed, which included patient data, treatment options, clinical trial results, standard treatment protocols, industry leaders, and regulatory requirements.

About the client

Our client is a major biopharmaceutical company that develops and commercializes medications, food ingredients, food additives, and veterinary medicines. They specialize in psychiatry and neurology, oncology, regenerative medicine, and cell therapy.

Objective

Our client wanted a market assessment that would pinpoint new growth opportunities and help them strategize accordingly. The study aimed to gain insight into the Hepatitis B treatment market in China, including its:

• Patient pool
• Treatment options
• Ongoing and potential clinical trials
• Standard treatment protocol
• Major companies operating in the market
• Regulatory landscape

Solution

We conducted a market assessment of hepatitis B treatment in China using a combination of primary and secondary research. Our respondent pool comprised gastroenterologists, hepatologists, and infectious disease physicians from the demand side, sales and market managers and heads from the supplier side, and industry/non-profit association specialists
Based on the information gathered from the research, the following insights were drawn:

• An overview of the addressable and serviceable market landscape in China: The market dynamics, the major biopharmaceutical manufacturers, and the treatment options.
• The regulatory landscape and pathways: An investigation of the regulatory environment, focusing on epidemiological data, the trial phases, and the key statistics about drug evaluation and approval.
• Future opportunities in the treatment market: Information regarding new products to be launched, statistics of market share, projected growth spikes, and the target country’s market share.